Can you provide the average price target for CLIMB BIO INC stock?
18 analysts have analysed CLYM and the average price target is 15.67 USD. This implies a price increase of 86.34% is expected in the next year compared to the current price of 8.41.
CLIMB BIO INC (CLYM) Forecast, Price Target & Analyst Ratings
NASDAQ:CLYM • US28658R1068
Current stock price
8.41 USD
+0.36 (+4.47%)
At close:
8.25 USD
-0.16 (-1.9%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CLIMB BIO INC (CLYM).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q1 / 2026
- EPS Estimate
- -$0.27
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$15.67
Upside
+ 86.34%
From current price of $8.41 to mean target of $15.67, Based on 18 analyst forecasts
Low
$8.08
Median
$14.28
High
$27.30
Price Target Revisions
1 Month
34.43%
3 Months
60.04%
Price Target Summary
18 Wall Street analysts provided a forecast for the next 12 months for CLYM. The average price target is 15.67 USD. This implies a price increase of 86.34% is expected in the next year compared to the current price of 8.41.
The average price target has been revised upward by 60.04% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
88.89%
CLYM was analyzed by 18 analysts. The buy percentage consensus is at 89. So analysts seem to be very confident about CLYM.
In the previous month the buy percentage consensus was at a similar level.
CLYM was analyzed by 18 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-08 | BTIG | Reiterate | Buy -> Buy |
| 2026-03-24 | B. Riley Securities | Initiate | Buy |
| 2026-03-18 | Truist Securities | Initiate | Buy |
| 2026-03-11 | Raymond James | Initiate | Strong Buy |
| 2026-03-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-03-06 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-03-06 | Baird | Maintains | Outperform -> Outperform |
| 2026-03-05 | Wedbush | Initiate | Outperform |
| 2026-02-13 | Piper Sandler | Initiate | Overweight |
| 2025-12-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-16 | William Blair | Initiate | Outperform |
| 2025-10-16 | BTIG | Reiterate | Buy -> Buy |
| 2025-10-13 | HC Wainwright & Co. | Initiate | Buy |
| 2025-09-30 | BTIG | Maintains | Buy -> Buy |
| 2025-09-22 | BTIG | Reiterate | Buy -> Buy |
| 2025-08-15 | Baird | Initiate | Outperform |
| 2025-06-06 | Oppenheimer | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q1 / 2026
- EPS Estimate
- -$0.27
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 12.36%
- Number of Analysts
- 14
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.12%
EPS (3 Months)
-31.54%
Next Earnings Summary
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 243.00% | N/A 195.70% | N/A 147.24% | N/A 81.41% | ||||||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | -67.786M | N/A -20.83% | N/A -20.05% | N/A -16.91% | N/A -0.62% | N/A -2.20% | N/A 65.14% | N/A 832.19% | N/A 185.43% | |
| EBIT YoY % growth | -7.45M | -20.93M -180.94% | -35.67M -70.43% | -45.14M -26.55% | -21.466M 52.45% | -27.003M -25.79% | -67.883M -151.39% | N/A -21.65% | N/A -28.24% | N/A -28.24% | N/A 3.03% | N/A -24.19% | N/A 14.34% | N/A 141.23% | N/A 530.30% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -1.72 73.28% | N/A 22.91% | N/A -20.77% | -0.89 44.42% | N/A -23.78% | N/A -15.91% | N/A -15.03% | N/A -59.72% | N/A -3.91% | N/A 10.04% | N/A 26.51% | N/A 36.08% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.27 12.36% | -0.28 -116.13% | -0.28 -48.97% | -0.28 -5.92% | -0.39 -43.29% | -0.32 -14.35% | -0.35 -22.52% | -0.39 -40.12% | -0.35 10.92% | -0.37 -14.29% | -0.38 -8.82% | -0.39 -0.44% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | ||||||||
| EBITDA Q2Q % growth | -20.502M | -18.972M -78.33% | -20.808M -40.36% | -21.624M -12.63% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -19.762M 14.14% | -20.359M -90.68% | -21.002M -41.03% | -21.749M -12.71% | -22.501M -13.86% | -24.088M -18.32% | -24.262M -15.53% | -24.446M -12.40% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-18.17%
EPS Next 5 Year
-22.33%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-20.95%
EBIT Next 5 Year
-12.72%
CLIMB BIO INC / CLYM Forecast FAQ
What are the consensus estimates for CLIMB BIO INC (CLYM) next earnings?
The consensus EPS estimate for the next earnings of CLIMB BIO INC (CLYM) is -0.27 USD and the consensus revenue estimate is 0 USD.
What is the consensus rating for CLIMB BIO INC (CLYM) stock?
The consensus rating for CLIMB BIO INC (CLYM) is 88.8889 / 100 . This indicates that analysts generally have a positive outlook on the stock.